day 1 agenda

6th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
at Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event)
Day -1(October 01, 2025)
Tentative Program
09:00-09:30 KeynoteTalk: Genistein (4′,5,7-trihydroxyisoflavone) corrects behavior and improves biochemical parameters in animal models of Alzheimer's disease through autophagy stimulation
Grzegorz Wegrzyn, University of Gdansk, Poland
09:30-10:00 KeynoteTalk: Alzheimer’s disease is likely a lipid-disorder complication as revealed by functional lipidomics and animal models
Xianlin Han, University of Texas Health Science Center at San Antonia, USA
10:00-10:30 KeynoteTalk: Neurogenesis And Plasticity Processes Are Similarly Affected And Damaged In Alzheimer´s Disease
José Julio Rodríguez Arellano, IKERBASQUE, Spain
Group Photo & Refreshment Break (10:30-10:50)
Technical session-I
Themes:
Alzheimer’s Research and Therapy,
Advances in Alzheimer’s and Dementia Research
10:50-11:10 Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer’s disease
Amanda J. Myers, University of Miami, USA
11:10-11:30 In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease 
Paul Chazot, Durham University, UK
11:30-11:50 The Alzheimer's Pathobiome Initiative: Using multiple global pan-domain and omic technologies to interrogate the link between infection and dementia 
Garth D. Ehrlich, Drexel University, USA
11:50-12:10 Slot Available
12:10-12:30 Biological prognosis toolbox for Alzheimer’s disease and other cognitive neurodegenerative diseases
Marc Teichmann, PITIE SALPETRIERE, France
12:30-12:50 Efficacy monitoring using amyloid and tau PET neuroimaging in Down syndrome populations
Bradley T Christian, University of Wisconsin-Madison, USA
12:50-13:10  Cerebral Proteome Adaptations to Amyloid Angiopathy are Prevented by Carbonic Anhydrase Inhibitors
Johan Magnus Palmfeldt, Aarhus University, Denmark
13:10-13:30 Slot Available
Lunch Break @ Restaurant (13:30-14:00)
14:00-14:20
Integrative Multi-Omics Analysis of APOE Genotype-Dependent Molecular Signatures in Alzheimer’s Disease
 
Gyungah R Jun, Boston University School Of Medicine, USA
14:20-14:40 Three scenarios for amyloid transformation 
Irena K. Roterman, Jagiellonian University – Medical College , Poland
14:40-15:00 Slot Available
15:00-15:20  Advancing dementia screening, care, and research in Kenya: challenges
and opportunities
Varghese John, University of California Los Angeles, USA
15:20-15:40  Advancing dementia screening, care, and research in Kenya: challenges
and opportunities
DAVID NDETEI, University of Nairobi / Africa Institute of Mental and Brain Health, Kenya
15:40-16:00 Slot Available
Refreshment Break(16:00-16:10)
Technical session-II
Themes:
Risk reduction and prevention &
Clinical Trials and Therapeutics
16:10-16:30 One-week inpatient cognitive behavioral therapy for insomnia: a retrospective study
Qifang Li, Tongji university, China
16:30-16:50 A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease
Alison Buchholz, The Johns Hopkins University School of Medicine, USA
16:50-17:10 Hearing Loss &Tinnitus – Reducing the Risk of Cognitive Decline
Keith N. Darrow, Worcester State University, USA
17:10-17:30 New Language Learning as a Cognitive Intervention in Aging: Behavioral and Neuroimaging Evidence
Ladan Ghazi Saidi, University of Nebraska Kearney, USA
17:30-17:50 Slot Available
17:50-18:10 Supplementation of Seaweed Extracts to the Diet Reduces Symptoms of Alzheimer’s Disease in the APPswePS1ΔE9 mouse model
Irfan Chaudhuri, Harvard University, USA
Note: This is a Tentative program, subjects and timings will changes.
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected]
Day-1 Concludes

day 2 agenda

Day -2(October 02, 2025)
Tentative Program
09:00-09:30 Keynote Talk: Exploring Immune Dysregulation and Gut-Nutrient Disruption in Alzheimer’s Disease Pathology
Catherine C L Wong, Peking Union Medical College Hospital, China
09:30-10:00 Slot Available
10:00-10:30 Slot Available
Group Photo & Refreshment Break (10:30-10:50)
Technical session-III
Themes:
Dementia diagnosis, treatment & Dementia care research and Practice
10:50-11:10 Cerebral Capillopathy Nexus of Neurodegenerative Disease
Charles R Joseph, Liberty University College of Osteopathic Medicine, USA
11:10-11:30  Short and Long-term Effects of Transcranial Alternating Electrical Stimulation Paired with Cognitive Exercises as a Treatment for Cognitive Impairment
Zahra Moussavi, University of Manitoba, Canada
11:30-11:50 Slot Available
11:50-12:10 Older adults with dementia: knowledge and attitudes of physicians in health units
ANA BEATRIZ QUINTES STEINER, UNIFESP, Brazil
12:10-12:30 Implications for the Down Syndrome Community of Availability of Anti-Amyloid Alzheimer’s Drug Treatments
Matthew P. Janicki, University of Illinois Chicago, USA
12:30-12:50  The efficacy of Sham rTMS stimulation
Brian Lithgow, University of Manitoba, Canada
12:50-13:10 Slot Available
Lunch Break @ Restaurant (13:10-14:00)
Technical session-IV
Themes:
Neurodegenerative Diseases & Amyloid and Tau Protein
14:00-14:20 Inflammation and tauopathies – a tale of therapeutic potential
Barbara Elena Stopschinski, University of Texas Southwestern Medical Center, USA
14:20-14:40 Non-inflammatory outcomes of P. gingilvalis outer membrane vesicles exposure in the embryonic mouse brain
Christian Lauber, Nationwide Children's Hospital, USA
14:40-15:00 Dihydromyricetin as a Dual-Target Neuroprotector: Clearing Tau and Aβ for Alzheimer's Disease Intervention
Judy Qiao, Towncom International Group, USA
15:00-15:20  Extracellular Tau and S100A9 proteins induce phagoptosis of live neurons
Vilma Borutaite, Lithuanian University of Health Sciences, Lithuania
15:20-15:40 Heparan sulfate modified protein signaling and neurodegenerative disease
Scott Selleck, Pennsylvania State University, USA
15:40-16:00 Slot Available
Refreshment Break(16:00-16:20)
16:20-16:40 Maternal and early life exposure induced AD- like pathophysiology
Aluru Parithathvi, Manipal School of Life Sciences, India
16:40-17:00 Semaglutide ameliorates Alzheimer’s disease and restores oxytocin in APP/ PS1 mice and human brain organoid models
Zhihui Zhong, Sichuan University West China Hospital, China
17:00-17:20  The Speech Disappears, but the Music Remains
Jaana Ruotsalainen, University of Jyväskylä, Finland
17:20-17:40  Genetic and biomarker research on dementia in rural Kenya: insights from the READD-ADSP project
Victoria Mutiso, Africa Institute of Mental and Brain Health, Kenya
Poster Presentations
PP-1 In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease 
Yunxi Zhang, Durham University, UK
PP-2 Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines
Anne-Cathrine Vogt, University of Bern, Switzerland
PP-3 Slot Available
PP-4 Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study
Norah Alanazi, Durham University, UK
PP-5 FUS-mediated Blood-brain barrier disruption for delivering anti-A? antibodies in 5XFAD Alzheimer’s disease mice
Christakis Damianou, Cyprus University of Technology, Cyprus
PP-6 Slot Available
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected]
Day-2 Concludes

posters agenda

Poster Presentations
PP-1 In vitro validation of RARβ-M, Ellorarxine, for use in Alzheimers disease 
Yunxi Zhang, Durham University, UK
PP-2 FUS-mediated Blood-brain barrier disruption for delivering anti-A? antibodies in 5XFAD Alzheimer’s disease mice
Christakis Damianou, Cyprus University of Technology, Cyprus
PP-3 Slot Available
PP-4 Concussion-Related Biomarkers in Retired Rugby Players and Implications for Alzheimer’s Disease and ALS Risk: The UK Rugby Health Study
Norah Alanazi, Durham University, UK
PP-5 Probing Monoclonal Antibody Specificity for Designing Alzheimer's Vaccines
Anne-Cathrine Vogt, University of Bern, Switzerland
PP-6 Slot Available
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected]

posters agenda

6th Edition of Innovations and State of the Art in
ALZHEIMER'S & DEMENTIA
at Oct 01 - 02, 2025 at Berlin, Germany (Hybrid Event)
Tentative Program
Day -1(October 01, 2025)
Virtual Program
09:00-09:20 CareWindow: Enhancing Communication for Seniors and Individuals with Disabilities
Zachary Bailey, Care Window, Australia
09:20-09:40 Slot Available
09:40-10:10 Keynote Talk: Sex-specific brain protection in the clinical scenario: the case of davuentide
Illana Gozes, Tel Aviv University, Israel
10:10-10:30 Enhancing the quality of life for family caregivers of people with Alzheimer's via virtual communities of practice
Montse Romero-Mas, University of Vic - Central University of Catalonia, Spain
10:30-10:50 Slot Available
10:50-11:10 From Phenotype Drug Screening to Biological Target identification for
Alzheimer’s disease-modifying development
SERGEANT Nicolas, University of Lille, France
11:10-11:30  Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial
Dean Ornish,  Preventive Medicine Research Institute, USA
11:30-11:50 Slot Available
11:50-12:10 Successes and Challenges: Insights from the first six months of the CONNECT program
Chitrali R. Mamlekar & Melissa A. Alunni, Misericordia University, USA
12:10-12:30 Slot Available
12:30-12:50 Clinicians' Reluctance to Implement a Deeply Demented Patient's Advance Directive: A Broken Moral Compass  
Norman L. Cantor, Retired from Rutgers University, USA
12:50-13:10 Slot Available
13:10-13:30 P re existing cognitive disorders and Long COVID neurocognitive sequelae : Why Do We Know So Little?
Caroline Jose,Vitalité Health Network, Canada
13:30-13:50 Slot Available
13:50-14:10 An integrative review about electrophysiological biomarkers of cognitive impairment in Alzheimer’s disease: A developing relationship
Ezra C. Holston, University of Nevada Reno, USA
14:10-14:30 Revised Criteria for Diagnosis and Staging of Alzheimer's Disease
Clifford R. Jack, Mayo Clinic, USA
14:30-14:50 Slot Available
14:50-15:10 Aging as a target for the prevention and treatment of Alzheimer’s disease
Raymond Scott Turner, Georgetown University., USA
15:10-15:30 Futuristic Alzheimer's therapy: acoustic-stimulated piezoelectric nanospheres for amyloid reduction
Manju Sharma, University of Georgia, USA
15:30-15:50 Slot Available
15:50-16:10 Enhancing Alzheimer's Disease Care Across Veterans Affairs Clinics: A Multi-site Quality Improvement Initiative
Arushi Kapoor, University of Pennsylvania, USA
Day-1 Concludes
   
Day -2(October 02, 2025)
Virtual Program
08:40-09:00 Understanding Depression Through Metaphors: Insights into Cognitive and Behavioral Patterns in Online Health Communities
Jiayi Shi,Xi'an Jiaotong University, China
09:00-09:20 A perspective on physical therapy approaches in motor function neurorehabilitation
Fengxue Qi, Beijing Sport University, China
09:20-09:40 Slot Available
09:40-10:00 Students’ core self-evaluation, psychological capital, and academic engagement: A case study of Romania and Serbia
Elena Mirela Samfira, University of Life Sciences „King Mihai I” from Timisoara, Romania
10:00-10:20 The crosstalk between CREB and PER2 mediates the transition between mania- and depression-like behavior
Xinling Wang, Freiburg University Medical Center, Germany
10:20-10:40 Exploring the Developmental Regulation Network of Human Serotonin Neurons via Florescent Reporter Systems
Jianfeng LU, Tongji University, China
10:40-11:00 Slot Available
11:00-11:20 OXYGEN-OZONE THERAPY AND COGNITIVE FRAILTY: A NONPHARMACOLOGICAL APPROACH TO POTENTIALLY RESOLVE IMMUNE AND INFLAMMATORY DYSFUNCTIONS
Antonio Carlo Galoforo, University of Pavia, Italy
11:20-11:40 Slot Available
11:40-12:00 Understanding Systems and Cognitive Process to Lead Change with Compassion
Elizabeth Wilhelm-Alderton & Renae Swanson, University of Wisconsin - Oshkosh, USA
12:00-12:20 Proposed Micronutrient Mixture, Probiotics, Collagen Peptides, Omega3, and  Cannabidiol (CBD) may Reduce Aging, and  Development and Progression of Alzheimer’s disease, and Improve its Treatment
Kedar N Prasad, Engage Global, Inc, USA
12:20-12:40 Severe COVID-19 is associated with transcriptomic signatures of aging in the human brain
Maria Mavrikaki, Harvard Medical School, USA
12:40-13:00 Slot Available
13:00-13:20 Psychosocial factors associated with the risk of developing psychosis in Mexico
Tecelli Domínguez Martínez, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico
13:20-13:40 Amyloid β fragments that suppress oligomers but not fibrils are cytoprotective 
Suren A. Tatulian, University of Central Florida, USA
13:40-14:00 Passive exposure to novel stimuli drives neural adaptation that encodes stimulus statistics in songbird auditory forebrain
David S. Vicario, Rutgers University, USA
14:00-14:20 Slot Available
14:20-14:40 Blood-brain barrier permeability contributes to cognitive impairment in the aftermath of SARS-CoV-2 infection: a role for cerebrovascular Wnt/beta-Catenin and Caveolin-1
Sarah E. Lutz, University of Illinois at Chicago, USA
14:40-15:00 Curcumin and omega-3 fatty acids: nutraceuticals against Alzheimer's disease
Luz Velasco, Universidad Veracruzana, Mexico
15:00-15:20 Slot Available
15:20-15:40 NeoRhythm: A Neurocardiac Electrophysiology-Based Explainable EEG and ECG System for Detection of Neonatal Seizures
Roshan Amurthur, Harker University, USA
15:40-16:00 How Children Learn To Understand Language Meanings
Stephen Grossberg, Boston University, USA
16:00-16:20 Enhancing cognitive functioning in dementia through at therapy: A randomized trial based on the Expressive Therapies Continuum (ETC) framework
Jinnie Jeon, Adler University, Canada
Abstract submissions are open now. To schedule your talk in the program please email to: [email protected]

Download